drugset / Trial / NCT04802837

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

NCT04802837

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.

Timeline

Start
2021-05-19
Primary completion
2021-09-17
Completion
2022-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ridinilazole Small molecule 200 mg
Comparator Vancomycin Other / unclassified 125 mg